Skip to main content

Table 1 CXCL13 in RA versus healthy controls and correlation with disease activity

From: A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis

Study Population Substrate RA vs healthy controls CXCL13 level (pg/ml) Correlation of CXCL13 with disease activity
Pandya et al. (2017) [14] N = 57. ERA. preDMARD Serum by ELISA ERA > HC Not published No correlation (data not presented): DAS28-CRP, DAS28-ESR, ESR, SJC28
Moura et al. (2017) [15] N = 33. ERA, EstRA csDMARD, DMARD Serum by ELISA ERA/EstRA > HC ERA = EstRA Not published (individual levels in figure) No correlation (data not presented): DAS28-ESR, ESR, SJC28, TJC28
Han et al. (2016) [16] N = 29. EstRA
TNFi (ADA & ETN)
Serum by ELISA   RA RF+: 372 (± 649), RA RF-: 40 (± 56) No correlation (data not presented): DAS28-ESR, ESR but correlated with change in DAS28-ESR (r = 0.54). 
Higher in ACPA & RF positive patients
Kumagai et al.* (2016) [17] N = 146. EstRA bDMARD Serum by ELISA EstRA > HC Not published Correlation: DAS28-CRP (r = 0.52)
Loza et al.* (2016) [18] N = 916. ERA
Anti-IL6
Serum by ELISA/MSD /Luminex EstRA > HC Not published  
Bugatti et al.* (2016) [19] N = 213. EstRA
csDMARD
Both, method not published   Not published Lower correlation with disease activity compared to CRP (data not presented). Predict failure to achieve LDA. Correlated with RF (data not presented). Higher in ACPA+ patients.
Han et al. (2015) [20] N = 111. ERA csDMARD, DMARD Serum by ELISA EstRA > HC Not published  
Yeo et al.* (2015) [21] N = 29. ERA preDMARD Synovial by mRNA qPCR   Not published Correlation: US power doppler (data not presented)
Bugatti et al.* (2014) [22] N = 71. ERA, EstRA csDMARD Synovial by mRNA qPCR   Not published ACPA & radiographic erosive disease associated greater expression CXCL13 (data not presented)
Greisen et al. (2014) [23] N = 114. ERA csDMARD, TNFi Serum by ELISA ERA > HC RA: 149 (75–245) HC: 50 (29–93) Correlation: B/L SJC28 (r = 0.34) PGA (r = 0.38) not TJC28
Bugatti et al.* (2014) [24] N = 205 csDMARD Serum by ELISA   Not published Correlation: ESR (r = 0.35), CRP (r = 0.36) DAS28 & US grey scale/power doppler (data not presented)
Moura et al. (2014) [25] Unpublished Serum by ELISA ERA/EstRA > HC Not published No correlation: DAS28-ESR, ESR, SJC28, TJC28 (data not presented)
Jones et al. (2014) [26]. EstRA N = 193
ERA N = 339
Serum by ELISA   EstRA RF+: 331 (250–431), EstRA RF-: 93 (71–124), ERA RF+: 324 (224–478), ERA RF-: 50 (35–78) Correlation DAS28-CRP (r = 0.52) in EstRA. Correlation RF in ERA (r = 0.54) & EstRA (0.45)
Sellam et al. (2013) [27] N = 278. ERA Serum by ELISA ERA > HC   Correlation: DAS28-CRP (r = 0.20)
Sherif et al. (2013) [28] N = 30. ERA Serum by ELISA ERA > HC RA + sSS: 137(±63), RA -sSS: 165(±91), HC: 12 (±2.2) Correlation: DAS28-ESR (r = 0.68), disease duration (r = 0.41)
Ahmed et al. (2013) [29] N = 30. ERA Serum by ELISA ERA > HC RA: 120–350 HC: 8–30 Correlation: DAS28-ESR (0.42) US power doppler (r = 0.69)
Setiadi et al.* (2013) [30] N = 1135. ERA Serum, method not published ERA > HC Not published  
Bugatti et al. (2012) [31] N = 180. ERA Serum by ELISA ERA > HC RA: 73 (47–117), HC: 54 (42–63) Correlation: DAS44-ESR (r = 0.35) SJC44 (r = 0.28) CRP (r = 0.42) ESR (r = 0.41) US grey scale (r = 0.27) US power doppler (r = 0.26)
Meeuwisee et al. (2011) [32] N = 229. ERA Serum by ELISA   Cohort 1: 167 (±86), Cohort 2: 156 (±99) Correlation: CRP (r = 0.43), ESR (r = 0.30), SJC66 (r = 0.23). Associated with radiographic erosive disease and failure to achieve remission. Levels higher in RF/ACPA patients.
  1. Unclear whether the two publications by Moura et al., in abstract form from 2014 and full publication from 2017 involve an analysis of the same patient population
  2. * Abstract only. ERA Early RA, EstRA Established RA, HC Healthy control, csDMARDs Conventional synthetic disease odifying anti-rheumatic drugs, bDMARDs Biologic disease-modifying anti-rheumatic drugs, TNFi Tumour Necrosis Factor inhibitor drug, ADA Adalimumab, ETN Etanercept, antiIL-6R Anti-interleukin 6 receptor, ELISA Enzyme-linked immunosorbent assay, ECLA Electrochemiluminescent (ECLA), MSD Meso Scale Discovery, qPCR Quantitative polymerase chain reaction (qPCR), DAS28 Disease activity score for 28 joint count, SJC Swollen joint count, TJC Tender joint count, PGA Patient global assessment, RF Rheumatoid factor, ACPA Anti–citrullinated peptide antibodies